MET and neoplasm: Although preclinical studies have shown that tumor cells with METamp display significantly increased sensitivity to MET inhibitors or MET tyrosine kinase inhibitors (MET-TKIs) [18–20], several clinical trials of MET inhibitors have failed in patients with METamp as determined by FISH [21–23].